Physician-pathologist Dr. Xueyan Chen is an expert in the diagnosis and classification of blood and lymph cancers using histology, immunohistochemistry, flow cytometry and molecular genetics. Before joining Fred Hutch, she served as UW Medicine’s Director of Developmental Hematopathology, the section that performs clinical trial testing for biopharmaceutical companies and study groups.
University of Washington, 2011-2012, Fellowship, Hematopathology
University of Wisconsin, 2007-2011, Residency, Anatomic and Clinical Pathology
Tufts University, 2003, PhD (Cell, Molecular & Developmental Biology)
Peking Union Medical College, 1998, MS (Cell Biology)
Beijing Medical University, 1995, MD
Correlate the prognostic impact of clinical response and measurable residual disease in acute myeloid leukemia
Characterize the immunophenotype of hematopoietic neoplasms associated with unique cytogenetic and molecular features
Assess prognostic impact of leukemic stem cells on outcomes in MDS/AML
Diagnosis and classification of blood and lymph cancers using histology, immunohistochemistry, flow cytometry and molecular genetics
Measurable residual disease testing by flow cytometry
Molecular testing including NGS myeloid and lymphoid gene panel and pan-Heme FusionPlex panel